



Webinar Invitation:
THE VERO TRIAL
5th December 2017

Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial¹

Who should attend: Healthcare professionals who manage and treat patients suffering with osteoporosis.

Lilly Medical are delighted to invite you to this webinar where Dr. David Kendler, lead author of the VERO trial, will present the results of the study. At the end of the presentation there will be a live Q & A session with the trial's lead Lilly physician, Dr. Fernando Marin, Senior Medical Fellow - Bone. During the live Q & A, Dr. Fernando Marin will be able to answer any questions you may have on the study.


The VERO trial is the largest controlled trial with Forsteo and the first 24-month, randomised, active-controlled trial which assessed fracture risk reduction as the primary endpoint in post-menopausal women with osteoporosis. It demonstrated that Forsteo is superior to risedronate in reducing incidence of new vertebral and clinical fractures during 24 months of therapy in patients with severe postmenopausal osteoporosis.

THE SESSIONS WILL BE 1 HOUR IN DURATION, PLEASE SELECT FROM THE OPTIONS BELOW: (CENTRAL EUROPEAN TIME)

5th DECEMBER 2017

- **11:00** local time Paris, Rome, Berlin - www.VEROSTUDY.com
- **14:00** local time Paris, Rome, Berlin - www.VEROSTUDY.com
- **18:00** local time Paris, Rome, Berlin - www.VEROSTUDY.com
- **20:00** local time Paris, Rome, Berlin - www.VEROSTUDY.com

PRESENTERS



Dr. David Kendler MD
University of British Columbia, Canada.
Professor of Medicine and Endocrinology.



Dr. Fernando Marin MD, PhD
Lilly Senior Medical Fellow - Therapeutic
Area Medical Lead Bone

1. Kendler DL, et al. *Lancet* (2017); [http://dx.doi.org/10.1016/S0140-6736\(17\)32137-2](http://dx.doi.org/10.1016/S0140-6736(17)32137-2)

Copyright © 2017 Eli Lilly and Company. All rights reserved.

Lilly products will be discussed in this webinar



JOIN THE WEBINAR TO LEARN MORE!